Patents by Inventor Friedrich Nolte
Friedrich Nolte has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230151118Abstract: The present invention relates to a non-agonist ligand of ARTC1, which inhibits the ADP-ribosyltransferase activity of ARTC1, or an inhibitor nucleic acid sequence capable of downregulating or inhibiting expression of a target nucleic acid sequence encoding ARTC1, for use in prevention or treatment of cancer. The invention also relates to a method for diagnosis of cancer.Type: ApplicationFiled: April 6, 2021Publication date: May 18, 2023Applicants: UNIVERSITÄT ZÜRICH, UNIVERSITÄTSKLINIKUM HAMBURG-EPPENDORFInventors: Friedrich NOLTE, Stephan MENZEL, Tobias SUTER, Michael HOTTIGER, Denise DORVIGNIT-PEDROSO, Jesus GLAUS-GARZON, Kathrin NOWAK, Fabio AIMI
-
Publication number: 20210332148Abstract: The invention relates to polypeptides specifically binding to CD38 and are therefore suitable for the diagnosis and for the therapeutic and prophylactic treatment of diseases which are characterized by increased CD38 expression. Conjugates and pharmaceutical compositions comprising the polypeptides are disclosed as well. In addition, the invention relates to the use of such polypeptides in methods for the detection of CD38 and/or CD38-expressing cells in a biological sample. A process for the purification and concentration of CD38 and/or CD38-expressing cells in which the antigen-binding polypeptides are used are also described.Type: ApplicationFiled: December 11, 2020Publication date: October 28, 2021Inventors: Friedrich Nolte, Peter Bannas, Kerstin Schütze, William Fumey, Levin Schriewer, Stephan Menzel, Catelijne Stortelers
-
Publication number: 20210139563Abstract: The present invention relates to fusion proteins comprising a cell surface marker specific VHH. In particular, the invention relates to bispecific VHH adaptor proteins, i.e. fusion proteins comprising an adeno-associated virus (AAV) specific VHH linked to a cell surface marker specific VHH. Moreover, the invention relates to a recombinant AAV which comprises a fusion protein in which a cell surface marker specific VHH is integrated into a capsid protein of the AAV. Also nucleotide sequences encoding such fusion proteins, vectors are contemplated. The invention moreover refers to uses of the fusion proteins and nucleic sequences for gene therapy.Type: ApplicationFiled: May 2, 2019Publication date: May 13, 2021Inventors: Friedrich Nolte, Anna Marei Mann
-
Patent number: 10865249Abstract: The invention relates to polypeptides specifically binding to CD38 and are therefore suitable for the diagnosis and for the therapeutic and prophylactic treatment of diseases which are characterized by increased CD38 expression. Conjugates and pharmaceutical compositions comprising the polypeptides are disclosed as well. In addition, the invention relates to the use of such polypeptides in methods for the detection of CD38 and/or CD38-expressing cells in a biological sample. A process for the purification and concentration of CD38 and/or CD38-expressing cells in which the antigen-binding polypeptides are used are also described.Type: GrantFiled: November 10, 2016Date of Patent: December 15, 2020Assignee: University Medical Center Hamburg-EppendorfInventors: Friedrich Nolte, Peter Bannas, Kerstin Schütze, William Fumey, Levin Schriewer, Stephan Menzel, Catelijne Stortelers
-
Publication number: 20200062833Abstract: The present invention contemplates isolated polynucleotide for the production of a VHH-containing heavy chain antibody in a mammal and vectors comprising said isolated polynucleotide. Moreover, the invention relates to a transgenic mammal comprising the vector for the production of a VHH-containing heavy chain antibody. Further, the invention relates to VHH-containing heavy chain antibodies as well as methods for the production and cloning of VHH-containing heavy chain antibodies.Type: ApplicationFiled: December 8, 2017Publication date: February 27, 2020Inventors: Friedrich NOLTE, Thomas EDEN, Janusz WESOLOWSKI, Stephan MENZEL
-
Patent number: 10544216Abstract: The present invention relates to biological materials against P2X7 and more in particular to polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. In particular, the biological materials of the present invention inhibit the biological activity of the P2X7 receptor, such as activation by ATP.Type: GrantFiled: January 19, 2018Date of Patent: January 28, 2020Assignees: Ablynx N.V., University Medical Center Hamburg-EppendorfInventors: Welbeck Owusu Danquah, Friedrich Nolte, Catelijne Stortelers, Toon Laeremans
-
Publication number: 20190276551Abstract: The invention relates to polypeptides specifically binding to CD38 and are therefore suitable for the diagnosis and for the therapeutic and prophylactic treatment of diseases which are characterized by increased CD38 expression. Conjugates and pharmaceutical compositions comprising the polypeptides are disclosed as well. In addition, the invention relates to the use of such polypeptides in methods for the detection of CD38 and/or CD38-expressing cells in a biological sample. A process for the purification and concentration of CD38 and/or CD38-expressing cells in which the antigen-binding polypeptides are used are also described.Type: ApplicationFiled: November 10, 2016Publication date: September 12, 2019Applicant: University Medical Center Hamburg-EppendorfInventors: Friedrich Nolte, Peter Bannas, Kerstin Schütze, William Fumey, Levin Schriewer, Stephan Menzel, Catelijne Stortelers
-
Publication number: 20180244769Abstract: The present invention relates to biological materials against P2X7 and more in particular to polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. In particular, the biological materials of the present invention inhibit the biological activity of the P2X7 receptor, such as activation by ATP.Type: ApplicationFiled: January 19, 2018Publication date: August 30, 2018Applicants: Ablynx N.V., University Medical Center Hamburg-EppendorfInventors: Welbeck Owusu Danquah, Friedrich Nolte, Catelijne Stortelers, Toon Laeremans
-
Patent number: 10023633Abstract: The present invention relates to a method for generating immunoglobulin sequences against cell-associated antigens, more particularly, antigens that are membrane-anchored. The invention also provides immunoglobulin sequences obtainable by the method of the invention. Specifically, the present invention relates to the generation of immunoglobulin sequences by use of DNA vaccination. More specifically, the present invention relates to generation of immunoglobulin sequences in camelids, preferably directed against cell-associated antigens, in particular antigens with multiple transmembrane spanning domains, including GPCRs and ion channels, by DNA vaccination. Furthermore, the present invention relates to said immunoglobulin sequences against cell-associated antigens, more particularly, antigens that are membrane-anchored, such as e.g. GPCRs and ion channels, more preferably ion channels.Type: GrantFiled: February 10, 2016Date of Patent: July 17, 2018Assignee: Ablynx N.V.Inventors: Toon Laeremans, Catelijne Stortelers, Friedrich Nolte, Maria Gonzalez Pajuelo, Joana Assunção, Philippe Van Rompaey
-
Patent number: 9908935Abstract: The present invention relates to biological materials against P2X7 and more in particular to polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. In particular, the biological materials of the present invention inhibit the biological activity of the P2X7 receptor, such as activation by ATP.Type: GrantFiled: May 31, 2013Date of Patent: March 6, 2018Assignees: Ablynx N.V., University Medical Center Hamburg-EppendorfInventors: Welbeck Owusu Danquah, Friedrich Nolte, Catelijne Stortelers, Toon Laeremans
-
Publication number: 20160264664Abstract: The present invention relates to a method for generating immunoglobulin sequences against cell-associated antigens, more particularly, antigens that are membrane-anchored. The invention also provides immunoglobulin sequences obtainable by the method of the invention. Specifically, the present invention relates to the generation of immunoglobulin sequences by use of DNA vaccination. More specifically, the present invention relates to generation of immunoglobulin sequences in camelids, preferably directed against cell-associated antigens, in particular antigens with multiple transmembrane spanning domains, including GPCRs and ion channels, by DNA vaccination. Furthermore, the present invention relates to said immunoglobulin sequences against cell-associated antigens, more particularly, antigens that are membrane-anchored, such as e.g. GPCRs and ion channels, more preferably ion channels.Type: ApplicationFiled: February 10, 2016Publication date: September 15, 2016Applicant: Ablynx N.V.Inventors: Toon Laeremans, Catelijne Stortelers, Friedrich Nolte, Maria Gonzalez Pajuelo, Joana Assunção, Philippe Van Rompaey
-
Patent number: 9260508Abstract: The present invention relates to a method for generating immunoglobulin sequences against cell-associated antigens, more particularly, antigens that are membrane-anchored. The invention also provides immunoglobulin sequences obtainable by the method of the invention. Specifically, the present invention relates to the generation of immunoglobulin sequences by use of DNA vaccination. More specifically, the present invention relates to generation of immunoglobulin sequences in camelids, preferably directed against cell-associated antigens, in particular antigens with multiple transmembrane spanning domains, including GPCRs and ion channels, by DNA vaccination. Furthermore, the present invention relates to said immunoglobulin sequences against cell-associated antigens, more particularly, antigens that are membrane-anchored, such as e.g. GPCRs and ion channels, more preferably ion channels.Type: GrantFiled: December 21, 2009Date of Patent: February 16, 2016Assignee: Ablynx N.V.Inventors: Toon Laeremans, Catelijne Stortelers, Friedrich Nolte, Maria Gonzalez Pajuelo, Joana Assunção, Philippe Van Rompaey
-
Publication number: 20150133637Abstract: The present invention relates to biological materials against P2X7 and more in particular to polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. In particular, the biological materials of the present invention inhibit the biological activity of the P2X7 receptor, such as activation by ATP.Type: ApplicationFiled: May 31, 2013Publication date: May 14, 2015Applicant: Ablynx N.V.Inventors: Welbeck Owusu Danquah, Friedrich Nolte, Catelijne Stortelers, Toon Laeremans
-
Publication number: 20100173799Abstract: The present invention relates to a method for generating immunoglobulin sequences against cell-associated antigens, more particularly, antigens that are membrane-anchored. The invention also provides immunoglobulin sequences obtainable by the method of the invention. Specifically, the present invention relates to the generation of immunoglobulin sequences by use of DNA vaccination. More specifically, the present invention relates to generation of immunoglobulin sequences in camelids, preferably directed against cell-associated antigens, in particular antigens with multiple transmembrane spanning domains, including GPCRs and ion channels, by DNA vaccination. Furthermore, the present invention relates to said immunoglobulin sequences against cell-associated antigens, more particularly, antigens that are membrane-anchored, such as e.g. GPCRs and ion channels, more preferably ion channels.Type: ApplicationFiled: December 21, 2009Publication date: July 8, 2010Applicant: Ablynx N.V.Inventors: Toon Laeremans, Catelijne Stortelers, Friedrich Nolte, Maria Gonzalez Pajuelo, Joana Assunção, Philippe Van Rompaey